Trial Profile
Phase 2 Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors in Refractory ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2023
Price :
$35
*
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Oct 2020 Interim results (n=20; as of Nov 2018) published in the Journal of Thoracic Oncology.
- 28 Jan 2020 Planned End Date changed from 1 Jan 2020 to 1 Jan 2022.
- 28 Jan 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2022.